BioCardia Inc.

BioCardia, Inc. operates as a clinical-stage regenerative medicine company. It develops novel therapeutics for cardiovascular diseases. The firm offers proprietary comprehensive biotherapeutic solutions for cardiovascular disease under the CardiAMP and CardiALLO brands. It operates in only one business segment, which is a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. The company was founded on January 12, 1994 and is headquartered in Sunnyvale, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioCardia reports successful fiscal year with promising clinical trials

BioCardia Inc. had a strong fiscal year with positive clinical trial results and increased revenues. While facing challenges related to trial data and timelines, the company's diversified product pipeline and financial stability offer growth opportunities in the healthcare sector.

BioCardia advances cell therapy programs amidst financial challenges and opportunities

BioCardia's Q1 2023 performance reflects ongoing investment in innovative cell therapy platforms. While facing financial challenges, the company remains focused on advancing clinical trials and engaging with regulatory authorities. Opportunities exist for BioCardia to leverage its expertise in cell therapy for strategic partnerships and further development.

BioCardia reports Q2 progress amidst trial setback and regulatory advancements

BioCardia's Q2 performance reflects progress in cell therapy platforms and regulatory advancements.
While facing challenges with the CardiAMP trial pause, the company maintains transparency and commitment to stakeholders.
Opportunities lie in addressing trial concerns, improving financial performance, and expanding market reach.

BioCardia reports Q3 results, progresses in cell therapy trials

BioCardia's Q3 performance reflects a mix of financial challenges and promising advancements in cell therapy trials for cardiovascular diseases.
Despite setbacks like the pause in the CardiAMP trial, the company's strategic initiatives and focus on regulatory approvals signal resilience and growth potential.
With a proactive approach to trial modifications and business development, BioCardia aims to leverage opportunities for future success in the biotech sector.

BioCardia reports positive trial data and strategic growth initiatives

BioCardia's Q4 2023 earnings call highlighted positive trial data, financial performance, strategic partnerships, and regulatory advancements, positioning the company for future growth.
While facing challenges in funding, timelines, and regulatory compliance, BioCardia's focus on innovation and market expansion presents opportunities for long-term success.
Investors should monitor BioCardia's progress in advancing its cell therapy platforms, securing approvals, and navigating regulatory landscapes for insights into its growth trajectory.

BioCardia reports positive trial results and financial improvements in Q1

BioCardia's Q1 2024 performance showcased positive trial results and improved financials, setting the stage for potential regulatory submissions and commercialization strategies.
While facing challenges in regulatory discussions and trial advancements, the company remains poised to capitalize on opportunities for growth and expansion.

BioCardia reports positive Q2 earnings, advances heart failure treatments

BioCardia demonstrated improved financial performance and significant advancements in clinical trials and product development, positioning the company for future growth
While facing challenges in regulatory compliance and financial sustainability, BioCardia's strengths in innovative treatments and partnership opportunities offer avenues for expansion
The company's focus on achieving key milestones like FDA clearances and trial completions underscores its commitment to advancing cardiovascular therapies and enhancing shareholder value

BioCardia reports strong Q3 performance, eyes partnerships for growth

BioCardia's Q3 2024 performance reflects improved financials and promising advancements in their lead cell therapy programs for heart failure
The company's strengths lie in efficient capital management, pipeline progress, and successful fundraising activities, positioning them for future growth
Challenges include clinical trial outcomes, regulatory hurdles, and balancing R&D momentum with cost management, while opportunities exist in partnerships and market expansion

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioCardia, Inc. is a clinical-stage biotherapeutic company. It engages in the business of developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. The company was founded on January 12, 1994 and is headquartered in Sunnyvale, CA.

SAN CARLOS, Calif., May  15, 2020  (GLOBE NEWSWIRE) --  BioCardia®, Inc.  [Nasdaq: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today reported financial results and business highlights for the first quarter of 2020 and filed its quarterly report on Form 10-Q for the three months ended March 31, 2020 with the Securities and Exchange Commission on May 15, 2020.

BioCardia Reports First Quarter 2020 Financial Results and Business Highlights

SAN CARLOS, Calif., April  30, 2020  (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today reported that it has accepted and implemented FDA-recommended modifications to the primary endpoint for the CardiAMP® Cell Therapy Heart Failure Trial and associated statistical analysis plan. The Agency proposed these modifications to support the potential for marketing approval for the therapy based on the currently enrolling pivotal trial.

Biocardia Announces FDA-Recommended Modifications to Primary Endpoint for Cardiamp Cell Therapy Heart Failure Trial to Support Marketing Approval

SAN CARLOS, Calif., April  28, 2020  (GLOBE NEWSWIRE) -- BioCardia®, Inc., (OTC: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced the issuance of United States Patent No. 10,632,281, entitled “Drug Delivery Catheters that Attach to Tissue and Methods for Their Use.” This new patent provides additional, broad protection for the Helix™ Biotherapeutic Delivery System and covers the use of the helical needle delivery system with a deflectable guide catheter. The U.S. Patent Office has extended the life of this patent for 2.8 years beyond the usual 20-year term.

BioCardia Awarded New U.S. Patent Covering Helix System for Local Biotherapeutic Delivery of Autologous and Allogenic Cells to the Heart

SAN CARLOS, Calif., Jan.  14, 2020  (GLOBE NEWSWIRE) --  BioCardia®, Inc.  [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Morph® DNA deflectable guide catheter used to guide the Helix™ Biotherapeutic Delivery System during CardiAMP™ cell therapy delivery in the heart.

Biocardia Announces FDA Clearance for Morph DNA Deflectable Guide Catheter

News for BioCardia Inc. Stock (BCDA)